Literature DB >> 25985274

Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.

Jordan R Willis, Gopal Sapparapu, Sasha Murrell, Jean-Philippe Julien, Vidisha Singh, Hannah G King, Yan Xia, Jennifer A Pickens, Celia C LaBranche, James C Slaughter, David C Montefiori, Ian A Wilson, Jens Meiler, James E Crowe.   

Abstract

Several HIV envelope-targeting (Env-targeting) antibodies with broad and potent neutralizing activity have been identified and shown to have unusual features. Of these, the PG9 antibody has a long heavy chain complementarity determining region 3 (HCDR3) and possesses unique structural elements that interact with protein and glycan features of the HIV Env glycoprotein. Here, we used the Rosetta software suite to design variants of the PG9 antibody HCDR3 loop with the goal of identifying variants with increased potency and breadth of neutralization for diverse HIV strains. One variant, designated PG9_N100(F)Y, possessed increased potency and was able to neutralize a diverse set of PG9-resistant HIV strains, including those lacking the Env N160 glycan, which is critical for PG9 binding. An atomic resolution structure of the PG9_N100(F)Y fragment antigen binding (Fab) confirmed that the mutated residue retains the paratope surface when compared with WT PG9. Differential scanning calorimetry experiments revealed that the mutation caused a modest increase in thermodynamic stability of the Fab, a feature predicted by the computational model. Our findings suggest that thermodynamic stabilization of the long HCDR3 in its active conformation is responsible for the increased potency of PG9_N100(F)Y, and strategies aimed at stabilizing this region in other HIV antibodies could become an important approach to in silico optimization of antibodies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25985274      PMCID: PMC4497764          DOI: 10.1172/JCI80693

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Native protein sequences are close to optimal for their structures.

Authors:  B Kuhlman; D Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

Review 2.  The chemistry of the antibody molecule.

Authors:  Peter G Schultz; Jun Yin; Richard A Lerner
Journal:  Angew Chem Int Ed Engl       Date:  2002-12-02       Impact factor: 15.336

3.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

4.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

5.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

6.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

7.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Authors:  Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori
Journal:  J Immunol Methods       Date:  2013-12-01       Impact factor: 2.303

8.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Authors:  Marie Pancera; Syed Shahzad-Ul-Hussan; Nicole A Doria-Rose; Jason S McLellan; Robert T Bailer; Kaifan Dai; Sandra Loesgen; Mark K Louder; Ryan P Staupe; Yongping Yang; Baoshan Zhang; Robert Parks; Joshua Eudailey; Krissey E Lloyd; Julie Blinn; S Munir Alam; Barton F Haynes; Mohammed N Amin; Lai-Xi Wang; Dennis R Burton; Wayne C Koff; Gary J Nabel; John R Mascola; Carole A Bewley; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369

9.  Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes.

Authors:  Bryan S Briney; Jordan R Willis; James E Crowe
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  17 in total

1.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Authors:  Nicole A Doria-Rose; Jinal N Bhiman; Ryan S Roark; Chaim A Schramm; Jason Gorman; Gwo-Yu Chuang; Marie Pancera; Evan M Cale; Michael J Ernandes; Mark K Louder; Mangaiarkarasi Asokan; Robert T Bailer; Aliaksandr Druz; Isabella R Fraschilla; Nigel J Garrett; Marissa Jarosinski; Rebecca M Lynch; Krisha McKee; Sijy O'Dell; Amarendra Pegu; Stephen D Schmidt; Ryan P Staupe; Matthew S Sutton; Keyun Wang; Constantinos Kurt Wibmer; Barton F Haynes; Salim Abdool-Karim; Lawrence Shapiro; Peter D Kwong; Penny L Moore; Lynn Morris; John R Mascola
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency.

Authors:  George K Lewis
Journal:  J Clin Invest       Date:  2015-05-18       Impact factor: 14.808

Review 3.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

4.  A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.

Authors:  Jon M Steichen; Ying-Cing Lin; Colin Havenar-Daughton; Simone Pecetta; Gabriel Ozorowski; Jordan R Willis; Laura Toy; Devin Sok; Alessia Liguori; Sven Kratochvil; Jonathan L Torres; Oleksandr Kalyuzhniy; Eleonora Melzi; Daniel W Kulp; Sebastian Raemisch; Xiaozhen Hu; Steffen M Bernard; Erik Georgeson; Nicole Phelps; Yumiko Adachi; Michael Kubitz; Elise Landais; Jeffrey Umotoy; Amanda Robinson; Bryan Briney; Ian A Wilson; Dennis R Burton; Andrew B Ward; Shane Crotty; Facundo D Batista; William R Schief
Journal:  Science       Date:  2019-10-31       Impact factor: 47.728

Review 5.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

6.  Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design.

Authors:  Clara T Schoeder; Samuel Schmitz; Jared Adolf-Bryfogle; Alexander M Sevy; Jessica A Finn; Marion F Sauer; Nina G Bozhanova; Benjamin K Mueller; Amandeep K Sangha; Jaume Bonet; Jonathan H Sheehan; Georg Kuenze; Brennica Marlow; Shannon T Smith; Hope Woods; Brian J Bender; Cristina E Martina; Diego Del Alamo; Pranav Kodali; Alican Gulsevin; William R Schief; Bruno E Correia; James E Crowe; Jens Meiler; Rocco Moretti
Journal:  Biochemistry       Date:  2021-03-11       Impact factor: 3.162

7.  An expanded benchmark for antibody-antigen docking and affinity prediction reveals insights into antibody recognition determinants.

Authors:  Johnathan D Guest; Thom Vreven; Jing Zhou; Iain Moal; Jeliazko R Jeliazkov; Jeffrey J Gray; Zhiping Weng; Brian G Pierce
Journal:  Structure       Date:  2021-02-03       Impact factor: 5.871

8.  Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains.

Authors:  Jinhui Dong; Jessica A Finn; Peter A Larsen; Timothy P L Smith; James E Crowe
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

9.  Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus.

Authors:  Ruijun Zhang; David R Martinez; Quang N Nguyen; Justin Pollara; Trina Arifin; Christina Stolarchuk; Andrew Foulger; Josh D Amos; Robert Parks; Jonathon E Himes; Minyue Wang; Regina W Edwards; Ashley M Trama; Nathan Vandergrift; Lisa Colvin; Ken Dewar; Nikoleta Juretic; Jessica Wasserscheid; Guido Ferrari; Hua-Xin Liao; Sallie R Permar
Journal:  Nat Commun       Date:  2016-07-06       Impact factor: 14.919

10.  Integrating linear optimization with structural modeling to increase HIV neutralization breadth.

Authors:  Alexander M Sevy; Swetasudha Panda; James E Crowe; Jens Meiler; Yevgeniy Vorobeychik
Journal:  PLoS Comput Biol       Date:  2018-02-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.